These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25690086)

  • 21. Nanomedicine for the treatment of Alzheimer's disease.
    Gregori M; Masserini M; Mancini S
    Nanomedicine (Lond); 2015; 10(7):1203-18. PubMed ID: 25929574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gelsolin as therapeutic target in Alzheimer's disease.
    Carro E
    Expert Opin Ther Targets; 2010 Jun; 14(6):585-92. PubMed ID: 20433353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Advances in Nanotherapeutic Interventions for the Treatment of Alzheimer's Disease.
    Dogra A; Narang RS; Narang JK
    Curr Pharm Des; 2020; 26(19):2257-2279. PubMed ID: 32321393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
    Kurakhmaeva KB; Djindjikhashvili IA; Petrov VE; Balabanyan VU; Voronina TA; Trofimov SS; Kreuter J; Gelperina S; Begley D; Alyautdin RN
    J Drug Target; 2009 Sep; 17(8):564-74. PubMed ID: 19694610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice.
    Zhang C; Wan X; Zheng X; Shao X; Liu Q; Zhang Q; Qian Y
    Biomaterials; 2014 Jan; 35(1):456-65. PubMed ID: 24099709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted Nanoparticles for the Treatment of Alzheimer's Disease.
    Martín-Rapun R; De Matteis L; Ambrosone A; Garcia-Embid S; Gutierrez L; de la Fuente JM
    Curr Pharm Des; 2017; 23(13):1927-1952. PubMed ID: 28025949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy.
    Desai BS; Monahan AJ; Carvey PM; Hendey B
    Cell Transplant; 2007; 16(3):285-99. PubMed ID: 17503739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The case for blood-brain barrier dysfunction in the pathogenesis of Alzheimer's disease.
    Jeynes B; Provias J
    J Neurosci Res; 2011 Jan; 89(1):22-8. PubMed ID: 21046564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alzheimer's Disease and its Related Dementia Types: A Review on Their Management
    Siafaka PI; Mutlu G; Okur NÜ
    Curr Alzheimer Res; 2020; 17(14):1239-1261. PubMed ID: 33602090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." The blood-brain barrier: a physical and conceptual challenge.
    Hachinski V; Lee TY
    Alzheimers Dement; 2009 Sep; 5(5):435-6. PubMed ID: 19751924
    [No Abstract]   [Full Text] [Related]  

  • 31. Nanoparticle-mediated approaches for Alzheimer's disease pathogenesis, diagnosis, and therapeutics.
    Hettiarachchi SD; Zhou Y; Seven E; Lakshmana MK; Kaushik AK; Chand HS; Leblanc RM
    J Control Release; 2019 Nov; 314():125-140. PubMed ID: 31647979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies.
    Loureiro JA; Gomes B; Coelho MA; do Carmo Pereira M; Rocha S
    Nanomedicine (Lond); 2014 Apr; 9(5):709-22. PubMed ID: 24827845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategy for effective brain drug delivery.
    Alam MI; Beg S; Samad A; Baboota S; Kohli K; Ali J; Ahuja A; Akbar M
    Eur J Pharm Sci; 2010 Aug; 40(5):385-403. PubMed ID: 20497904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer's Disease.
    Nguyen TT; Vo TK; Vo GV
    Adv Exp Med Biol; 2021; 1286():183-198. PubMed ID: 33725354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alzheimer's disease drug development and the problem of the blood-brain barrier.
    Pardridge WM
    Alzheimers Dement; 2009 Sep; 5(5):427-32. PubMed ID: 19751922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted drug delivery across the blood brain barrier in Alzheimer's disease.
    Rocha S
    Curr Pharm Des; 2013; 19(37):6635-46. PubMed ID: 23621533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current perspectives on pharmacotherapy of Alzheimer's disease.
    Chopra K; Misra S; Kuhad A
    Expert Opin Pharmacother; 2011 Feb; 12(3):335-50. PubMed ID: 21222549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The treatment of Alzheimer's disease using Chinese medicinal plants: from disease models to potential clinical applications.
    Su Y; Wang Q; Wang C; Chan K; Sun Y; Kuang H
    J Ethnopharmacol; 2014 Mar; 152(3):403-23. PubMed ID: 24412377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The future of Alzheimer's disease: the next 10 years.
    Hampel H; Prvulovic D; Teipel S; Jessen F; Luckhaus C; Frölich L; Riepe MW; Dodel R; Leyhe T; Bertram L; Hoffmann W; Faltraco F;
    Prog Neurobiol; 2011 Dec; 95(4):718-28. PubMed ID: 22137045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.